Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Denali Water Solutions, LLC Acquires Stock of Veris Environmental, LLC and AWS Dredge, LLC

Russellville, Arkansas – October 26, 2020 – Denali Water Solutions, LLC announced that it has acquired the stock of Veris Environmental, LLC and AWS Dredge, LLC. Veris Environmental, LLC is a residuals management services company providing biosolids recycling and transportation, dewatering, digester cleaning, lagoon services and sediment removal, and land application services in the western…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
Denali Water Solutions, LLC Acquires Stock of Veris Environmental, LLC and AWS Dredge, LLC

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Russellville, Arkansas – October 26, 2020 – Denali Water Solutions, LLC announced that it has acquired the stock of Veris Environmental, LLC and AWS Dredge, LLC. Veris Environmental, LLC is a residuals management services company providing biosolids recycling and transportation, dewatering, digester cleaning, lagoon services and sediment removal, and land application services in the western United States. AWS Dredge, LLC, is a service provider to hard rock mines in the western United States. The stock purchase aligns with Denali’s strategic growth plan of expansion to additional markets and geographical regions.

“We are thrilled to welcome the Veris Environmental and AWS Dredge teams to the Denali family. This decision aligns with our goal of building a team with strong and experienced leaders to enhance our safety-focused and quality residuals management services to our customers and to the communities we live and work in,” noted Andy McNeill, CEO of Denali Water Solutions.

Kipp Parker, the majority owner of Veris Environmental and founder of Parker Ag Services, stated that he is grateful to have formed a relationship with Denali Water Solutions and is looking forward to seeing the expansion of the stewardship of the company he has built over the years.

Jay Holmes, CEO of Veris Environmental and founder of Liquid Waste Management, and Mike Scharp, Vice President of Marketing and Technical Services of Veris Environmental and a long term partner in Parker Ag Services, have both expressed excitement about joining the Denali Water Solutions leadership team as Denali expands their market area into the Rocky Mountain region of the United States.

About Denali Water Solutions

Denali Water Solutions is a specialty waste and environmental services company that believes it is the collective responsibility of us all to protect the quality of water and natural resources through recycling waste in sustainable ways, can be beneficially reused, and reduce or eliminate the use of landfills. Our vision is to meet this responsibility by offering innovative and economically effective solutions for the management, handling, recycling, disposal, and conversion of organic waste materials through beneficial reuse, composting, and anaerobic digestion for the customers and communities we serve. Denali Water Solutions is a full-service provider throughout the organic waste management cycle; processed waste is dewatered then recycled through liquid and solid land applications, chemical treatment, and composting. Beneficial use and recycling methods create sustainability benefits through fertilizing farmland, enhancing soil health with compost, and generating clean water. To learn more, please visit here.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512